DEDICATED TO
Our Platform Technology
DEDICATED TO
Our Products
DEDICATED TO
Investment Highlights
DEDICATED TO
Our Team
DEDICATED TO
Our News
DEDICATED TO
DEDICATED TO
DEDICATED TO
DEDICATED TO
DEDICATED TO
Curewize is a leader in the field of personalized medicine, diagnostics and predictive medicine. The Company's goal is to improve the survival rate and overall health outcome of cancer patients. Our proprietary platform technology measures microRNA (miRNA) profiles in patients’ biofluids. MiRNAs control gene activity, and are considered superior biomarkers for diagnosis and personalized treatment decisions due to their direct link to cancer mechanisms and stability in human biofluid samples. The company’s initial product is ProALL, a groundbreaking lab test for deciding on the intensity of treatment of acute lymphoblastic leukemia (ALL) patients. Lead Product The ProALL bone marrow (BM) lab test is our lead product, measuring the level of three miRNA molecules in samples taken a...
Read More
Curewize is positioned with an accurate, industrial standard proprietary platform technology. Our mangement are experts in the development and commerc
Read More 
Translate and transfer microRNA biomaker lab tests to clincial practice. Connecting groundbreaking academic discoveries to Curewize platform technolgy
Read More 
Personalized medicine seperates cancer patients into different groups for precise treatment decisions and tailored medicine. Personalized medicine is
Read More 
Create tools based on microRNA biomarkers for tailoring cancer patients optimal treatment. Curewize is industrializing cancer-specific prognosti
Read More 
Date : 03.04.2018
Curewize successfully completed the clinical trial of its lead product ProALLBM on a cohort of acute lymphoblastic leukemia (ALL) patients from a European National Registry Study. ProALLBM is being produced for deciding on ALL patients risk-based treatment group, varying from standard to i ...
Date : 24.01.2017
Curewize Health Ltd., a diagnostic company focused on the development of proprietary diagnostics for the treatment of Acute Lymphoblastic Leukemia (ALL), announced that the Israeli Patent Authority has indicated on January 24, 2017 that it intends to grant a patent relating to Curewize’s ProAL ...
Date : 07.12.2016
Curewize presented results of our retrospective clinical trial showing the correlation of ProALL microRNA in blood to microRNA in Bone Marrow at the 58th Annual Meeting and Exposition of the American Society of Hematology in San Diego December 2016. The Poster presented by Curewize's team "Mir ...
